Combination treatment of ODF2L-targeted therapy via an siRNA-loaded LNP would be expected to benefit patients experiencing severe side effects such as histopathological toxicity after receiving a relatively high dose of a WEE1 inhibitor alone, or patients who have received WEE1 inhibitor–based therapy but whose cancer recurred, in part because of the induction of ODF2L during the treatment. The gene discussed is WEE1; the disease is cancer.